Crow's Feet Wrinkles Clinical Trial
Official title:
Feasibility and Acceptability of a TEOSYAL® PureSense Redensity [I] Injection Using MicronJet® Needle in the Treatment of Crow's Feet Wrinkles
| Verified date | May 2015 |
| Source | Teoxane SA |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to evaluate the feasibility and acceptability of a TEOSYAL®
PureSense Redensity [I] injection using MicronJet® needle in the treatment of crow's feet
wrinkles.
It is a monocentric, open-blind, prospective, pilot study. 3 injections sessions spaced with
an interval of 3 weeks. The last visit will be performed 3 weeks after the last injection.
Only, one group of 15 healthy volunteers will be included.
| Status | Completed |
| Enrollment | 15 |
| Est. completion date | October 2015 |
| Est. primary completion date | October 2015 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 25 Years to 75 Years |
| Eligibility |
Inclusion Criteria: - Healthy volunteer (desiring an aesthetic improvement of crow's feet area). - Crow's feet score between 3 to 5 on both sides. - Psychologically able to understand the study related information (For example, it will be difficult to include a foreigner who does not speak French, unaccompanied by a translator or subject who can't read the information note and the volunteer diary). - Having given his informed consent. - Female subjects of childbearing potential should use a medically accepted contraceptive regimen (for example, hormonal contraception, intrauterine contraceptive device or surgical sterilization…), during all the study and at least 1 month after the study end. Exclusion Criteria: - Pregnant or nursing woman or planning a pregnancy during the study (according to the product IFU). - Volunteer having a previous history of cutaneous cancer or all others type of cancer. (to verify that the volunteer is healthy) - Suffering from a serious or progressive diseases, which, put the subject at undue risk (as for example diabetes, auto-immune pathology, cardiac pathologies, hepatic deficiency, epilepsy )(to verify that the volunteer is healthy) - With scars, infection, or other pathology on the injection sites. (as rosacea, herpes, acne, blotches on the injection sites. (the product injection can't be performed on a damaged skin and the wrinkles can be seen by the investigator - according to the product IFU) - With active skin disease within 6 months prior to study entry. (according to the product IFU) - With severe rheumatism fever. - Predisposed to keloidosis (itchy skin or skin rash and hives) or hypertrophic scarring. ( - With a known allergy to one of the ingredients of the tested products (as hyaluronic acid hypersensitivity or lidocaine or local anesthetic: 70° Alcohol or Chlorhexidine allergy). (according to the product IFU) - With multiple allergies or anaphylactic shock history. (according to the product IFU) - With coagulation troubles, abnormal bleeding as hemophiliac or von Willebrand disease. - Under an anti-coagulant treatment in the 2 weeks preceding the study. - Under >30,000 IU/day oral vitamin E in the 1 week preceding the study. - Under corticosteroids in the 2 weeks preceding the study and used in the severe allergy treatment. - Under interferon in the 1 month preceding the study and used for antiinfectious or antioncogene proprieties. - Having an aspirin (ASA - Acetyl Salicylic Acid) or a non-steroidal anti-inflammatory treatment in the last 15 days (the subject can still be bled easily). - Having a peeling, laser or ultrasound-based treatment. (according to the product IFU) - Having any medication which may interfere, at the interpretation of the investigator, with the study objectives in term of efficacy and safety tolerance (currently, the interactions with an other HA product are not tested, it is not possible to inject Teosyal® PureSense Redensity I into sites where other filling implants are present - according to the product IFU). - Suspected to be non-compliant according to the investigator's judgment (for example, a subject for which the investigator knows that he cannot come to all the visits in reason of holidays or moving, can be not include in this study) - Enrolled in another clinical trial or being in an exclusion period for a previous study. |
| Country | Name | City | State |
|---|---|---|---|
| Switzerland | Docteur MICHEELS | Geneva |
| Lead Sponsor | Collaborator |
|---|---|
| Teoxane SA |
Switzerland,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Adverse event | From Day 0 to Day 63 (end of study) | ||
| Other | Local reactions collected by the subject | Local reactions collected by the subject on a 14-day subject diary | at Day 0, Day 21 and D42 | |
| Other | Change from Baseline of crow's feet scale (Aesthetic Improvement) for efficacy Measurement | 7-grade scale | at Day 21, Day 42 and Day 63 (end of study visit) | |
| Other | Global Aesthetic Improvement scale for efficacy measurement | 5 grade likert scale | at Day 21, Day 42 and Day 63 (end of study visit) | |
| Other | Product leakage at the skin area, in comparison with a classic needle | 4-grade scale | at Day 63 (end of study visit) | |
| Other | Pain sensation at the insertion, in comparison with a classic needle | 4-grade scale | at Day 63 (end of study visit) | |
| Primary | Crow's feet responder for the feasibility outcome | The crow's feet responder is defined as a crow's feet score with at least one grade of improvement between D0 and D63. As the subject can be treated on each side, each subject can give two answers. | Day 63 (end of study) | |
| Secondary | Subject satisfaction for acceptability outcome | 5-grade Likert scale | at Day 0, Day 21, D42 and D63 (end of study visit) | |
| Secondary | Pain evaluated by the subject | Subjective visual analogue scale (0 to 10 cm) | at Day 0, Day 21 and D42 |